Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Newspaper Publication for Notice of 35th AGM and E-Voting Information
Source: Bse
Caplin Point Laboratories Limited (CAPLIPOINT)
Large CapPharma stocks · Large cap · NSE
Caplin Point Laboratories is a vertically integrated pharma company manufacturing intermediate APIs and finished formulations for regulated markets. It has a strong presence in Latin America and is expanding its footprint in the US sterile injectable space, focusing on a customer-proximity inventory model and digitalized manufacturing.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result12 Aug, 01:41 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
67BullishSMA20 -2.2% / mo · RSI oversold · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 46
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
CAPLIPOINTD candles · FIT view+31.4%Latest close ₹2258.80 on 2026-10-19
Bar
-1.8%
RSI
27
MACD hist
-46.38
52W pos
51%
2026-10-19O ₹2301.30H ₹2322.10L ₹2255.00C ₹2258.80Vol 70,397 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
CAPLIPOINTNifty PharmaNifty 500
- CAPLIPOINT
- -14.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -9.2 pp
Chart stats
19 Oct 2026- From 52W high
- -24.5%
- 52W range position
- 51%
- ATR (14)
- 4.5%
- Volume vs 20D
- 0.37x
- Avg traded value
- ₹48.3 Cr
- 20D price channel
- ₹2,248.1 - ₹2,990
₹2,990
₹1,500.3 - ₹2,990
₹102.2
Latest completed session
20-session average
30.5% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED61
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average42
Revenue +19.6% · PAT +18.5% YoY
Technical
Bullish67
Price trend and sector-relative-strength timing.
Valuation
Legacy model+42.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence85
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 42/100margin compression · Rev +20% YoY · PAT +19% YoY
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹610 Cr | +19.6% | +1.7% |
| EBITDA | ₹213 Cr | +19.7% | +4.4% |
| Operating margin | 35.0% | +0 bps | +100 bps |
| PAT | ₹179 Cr | +18.5% | +3.5% |
| PAT margin | 29.3% | -27 bps | +51 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 26.30
- P/B
- 5.19
- EV/EBITDA
- 20.24
- Market Cap
- 17493.00Cr
Profitability
- ROE
- 20.90%
- ROCE
- 24.20%
- ROA
- 16.79%
- Dividend Y
- 0.35%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 21.00%
- Revenue 3Y
- 14.00%
- EPS 3Y
- 19.00%
Balance Sheet
- Debt/Equity
- 0.07
- Interest Coverage
- 797.00×
- Altman Z
- 8.68
- Book Value
- 443.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 6/5
- OCF
- 523.00 Cr
- EPS TTM
- 87.53
Shareholding
- Promoter Hold
- 70.57%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 54%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 2,287+4.6% vs prev
Net Profit
₹ CrLatest: 650+20.1% vs prev
Return on Equity
%Latest: 4,333+26898.9% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 27. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~2.2% over last month) — short-term momentum negative.
- RSI(14) at 27 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- 24% off 52W high · 51% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
80
RS percentile
Stage 1 Base / Transition
1M return
-17.8%
3M return
-14.7%
6M return
+28.9%
1Y return
+12.3%
RS 1D
-1
RS 20D
-10
Sector rank
#1
Industry rank
#3
Stage evidence
- Price is within 0.8% of the 30-week proxy.
- The 30-week proxy changed +5.7% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 114.27-0.83%
RS vs Nifty 500114
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · UNDERVALUEDValuation10/30
Growth17/25
Quality14/20
Balance Sheet11/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
61
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
61/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 42.6%.
- Balance sheet contributes 11/15 to the score.
Main drags
- Valuation is weaker at 10/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 17/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
26.3
PB
5.2
EV/EBITDA
20.2
ROE
20.9%
ROCE
24.2%
FCF Yield
—
Debt/Equity
0.1
MoS
+42.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
61
Previous: 61
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+42.6%
Previous: +42.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
59
59
59
59
59
61
61
61
61
61
61
61
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹934.05
-141.8% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹3,938.85
+42.6% MoS
PEG
1.30
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ERIS
Large
Eris Lifesciences Limited
Pharmaceuticals
match 167
55
24.5
18.7%
+47%
FAIR VALUE
PFIZER
Large
Pfizer Limited
Pharmaceuticals
match 165
33
117.0
19.8%
-738%
WATCHLIST
ALIVUS
Large
Alivus Life Sciences Limited
Pharmaceuticals
match 165
29
47.0
—
+14%
OVERVALUED
ASTRAZEN
Small
AstraZeneca Pharma India Limited
Pharmaceuticals
match 159
43
85.2
23.3%
-98%
WATCHLIST
APLLTD
Mid
Alembic Pharmaceuticals Limited
Pharmaceuticals
match 159
34
21.0
13.4%
-455%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-10-12T09:41:02.595Z
Management commentary snapshot
Q1 FY27 revenue grew 20% YoY, driven by 26% US market growth and 18% conventional market growth, with EBITDA margin improving to 38.4%.
Caplin Point delivered robust Q1 FY27 results, with strong top-line growth driven by both US and conventional markets. The company is strategically investing in capacity expansion, vertical integration (API, Amaris Clinical), and market penetration (Mexico distribution, new geographies) using internal accruals. While PBT profitability in "rest of the world" saw a slight decline, management attributes it to product mix and increased marketing expenses, not a structural issue. The focus on direct customer relationships and advanced manufacturing capabilities positions it for future growth, though execution on new capacity ramp-up and market entry remains key.
Growth engines
US Sterile Injectable Market
We continue to see robust growth in cash flow, bottom line and topline in the US, building an integrated platform from R&D and manufacturing to commercial operations.
Emerging Markets (LatAm)
Our emerging market business continues to be a very dependable growth engine, built over two decades through a strong distribution network and deep market understanding.
New Geographies/Segments
Expanding addressable opportunity through new areas such as oncology, branded generics, and new markets like Chile and Mexico.
Vertical Integration
Our own API will augment the platform, giving us very good control over our supply chain, a critical area in this space.
Capacity and execution
CSL Line 6 & Oncology Project Capitalization
Depreciation increased by INR 5.3 crores primarily due to the capitalization of Line 6 in CSL and the oncology project.
Kakkalur Injectable & Vizag API Plant
Injectable project in Kakkalur and Vizag API plant saw some additions over and above initial purchases.
New Sterile Lines
Currently have 6 lines, a seventh is coming up. Oncology facility has a line. Five more lines from Phase 3 expected by this time next year, totaling 13 lines with visibility.
Amaris Clinical Expansion
Investing in the expansion of Amaris Clinical for BE studies, increasing from 70 beds up to 120 beds in the near future.
Tailwinds
Strong Cash Position
Free cash reserves stand at INR 1,502 crores and total liquid assets are in the region of INR 2,875 crores.
Customer Proximity Inventory Model
20% of fast-moving products always stay in warehouses next to the customer, carrying six months of stock, creating a fan club for Caplin products.
Digitalization & Automation
Digitizing entire factories, introducing video masters for visual learning, and planning AI cameras and digital twins for remote monitoring and transparency.
Integrated US Platform
Building an integrated platform from R&D and manufacturing to regulatory capabilities, with own label commercial operations and direct customer relationships in the US.
Headwinds
Capacity Constraints
Current challenge is not lack of orders but lack of capacity in two major factories, CP1 in Pondicherry and CSL in Gummidipundi.
Increased Working Capital
Conscious decision to increase warehouse stock by INR 76 crores and RM & PM inventory by INR 15 crores; receivables also up by INR 46 crores.
Geopolitical Situations
Increased warehouse stock to shield against potential supply chain disruption and ensure continuity amid ongoing geopolitical situations.
Raw Material Price Fluctuations
Increased RM & PM inventory to shield against potential increases in raw material prices arising from escalating oil fluctuations.
Risk radar
Execution Risk on New Capacity
Completing new factories may take one to two and a half years, with business increasing manyfold only after completion.
Regulatory Approval Delays for New Facilities
Any product converted from a current facility to a new one will take about 9 to 10 months to become commercially operational due to Post Approval Supplements.
PBT Profitability in Rest of World
PBT profitability for the rest of the world declined from 37.5% in Q1 FY26 to 33-odd percent in Q1 FY27, attributed to product mix and increased expenses.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare YOY
The CFO explicitly compares Q1 FY27 results (revenue, PBT, PAT, US revenue, gross profit) to the "previous year" or "last one year," indicating a primary YoY comparison for core financial performance.
Sector KPIs management disclosed
Overall Revenue Growth
Overall revenue grew by 20%.
US Market Revenue Growth
26% growth in the US market.
Conventional Market Revenue Growth
18% growth in our conventional market.
US Subsidiary Revenue Growth
US subsidiary revenue increased from INR 14.4 crores in the previous year to INR 43.7 crores, a three-fold increase.
Management forward view
Future Growth Ambition
Ambition is not just to become a larger pharmaceutical company, but to build a platform with strong presence across geographies, broader portfolio, and greater vertical integration.
Strategic Acquisitions
Plan to buy a distribution company in Mexico to better understand product selection and customer identification.
Focus on Private Market
Will focus more on the private market in bigger geographies where there is less competition for generics from India and China.
Long-term Vision
Prefer to be one among the top 20 companies of the country by building international standard facilities for regulated markets worldwide.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| New Sterile Facility Commissioning | Line 7 starting in 6-7 months; 5 more lines from Phase 3 by this time next year. | Timely commissioning and ramp-up of new sterile lines and facilities. |
| Mexico Distribution Acquisition | Evaluating 3-4 companies; due diligence pending. | Announcement of a meaningful acquisition of a distribution company in Mexico. |
| US Product Launches | 39 out of 60-odd ANDAs launched; 40+ products in pipeline. | Progress on launching the remaining ANDAs and new pipeline products in the US. |
| Cash Flow from Operations (CFO) | INR 95 crores for Q1 FY27, impacted by working capital increase. | Improvement in CFO from Q2 FY27 onwards, with profits flowing into CFO as working capital normalizes. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
85Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 98th percentile of the scored universe and 98th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 20 Oct 2026
management-trust-v1
24 docs text-extracted · 8 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
98th percentile
overall median 67 · Pharma: 98th pctile, median 70 · Large: 94th pctile, median 73
Evidence depth
Financial-only
24 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 70.6%.
- ▸Promoter pledge is zero.
- ▸6 years of positive FCF.
- ▸Debt/equity is 0.07.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Caplin Point Laboratories Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Company Ir
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 12 Aug - Dr. Sridhar Ganesan reappointed MD for 2 years; D. Muralidharan appointed WTD from August 12, 2026.
Source: Bse
Concall transcript
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 19 Aug - Transcript for Earnings call- Q1- FY 2026-27
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 22 Jun - Newspaper advertisement for transfer of Unclaimed dividend and shares to IEPF
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Company Ir
Investor presentationMay 2026
May 2026 · PPT
Source: Company Ir
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 May - Caplin Point will attend TRINITY INDIA 2026 investor conference on May 28, 2026 in Mumbai.
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 14 May - Caplin Steriles received USFDA approval for Foscarnet Sodium Injection on May 14, 2026.
Source: Bse
Concall transcript
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 21 May - Transcript for Earnings call- Q4- FY 2025-26
Source: Bse
Annual report
Annual Report 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.